Neumora Therapeutics Inc
NMRA
查看详细走势图
1.780USD
-0.030-1.66%
收盘 12/26, 16:00（美东）报价延迟15分钟
288.27M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.66%
5天
+1.71%
1月
-22.27%
6月
+135.17%
今年开始到现在
-83.21%
1年
-84.29%
查看详细走势图
TradingKey Neumora Therapeutics Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Neumora Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
8
位分析师
买入
评级
9.167
目标均价
+318.57%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Neumora Therapeutics Inc亮点
亮点风险
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值合理
公司最新PE估值-1.72，处于3年历史合理位
机构减仓
最新机构持股88.64M股，环比减少29.97%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值132.04K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.47
Neumora Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Neumora Therapeutics Inc简介
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
公司代码NMRA
公司Neumora Therapeutics Inc
CEOBerns (Paul L)
网址https://neumoratx.com/
常见问题
Neumora Therapeutics Inc(NMRA)的当前股价是多少？
Neumora Therapeutics Inc(NMRA)的当前股价是 1.780。
Neumora Therapeutics Inc的股票代码是什么？
Neumora Therapeutics Inc的股票代码是NMRA。
Neumora Therapeutics Inc股票的52周最高点是多少？
Neumora Therapeutics Inc股票的52周最高点是11.570。
Neumora Therapeutics Inc股票的52周最低点是多少？
Neumora Therapeutics Inc股票的52周最低点是0.611。
Neumora Therapeutics Inc的市值是多少？
Neumora Therapeutics Inc的市值是288.27M。
Neumora Therapeutics Inc的净利润是多少？
Neumora Therapeutics Inc的净利润为-243.79M。
现在Neumora Therapeutics Inc(NMRA)的股票是买入、持有还是卖出？
根据分析师评级，Neumora Therapeutics Inc(NMRA)的总体评级为买入，目标价格为9.167。
Neumora Therapeutics Inc(NMRA)股票的每股收益（EPS TTM）是多少
Neumora Therapeutics Inc(NMRA)股票的每股收益（EPS TTM）是-1.463。
相关品种
